- Volume 5 Issue 2
DOI QR Code
Systematic Approach for Analyzing Drug Combination by Using Target-Enzyme Distance
- Park, Jaesub (Department of Bio and Brain Engineering, Korea Advanced Institute of Science and Technology) ;
- Lee, Sunjae (Department of Bio and Brain Engineering, Korea Advanced Institute of Science and Technology) ;
- Kim, Kiseong (Department of Bio and Brain Engineering, Korea Advanced Institute of Science and Technology) ;
- Lee, Doheon (Department of Bio and Brain Engineering, Korea Advanced Institute of Science and Technology)
- Received : 2013.04.22
- Accepted : 2013.04.23
- Published : 2013.06.28
Recently, the productivity of drug discovery has gradually decreased as the limitations of single-target-based drugs for various and complex diseases become exposed. To overcome these limitations, drug combinations have been proposed, and great efforts have been made to predict efficacious drug combinations by statistical methods using drug databases. However, previous methods which did not take into account biological networks are insufficient for elaborate predictions. Also, increased evidences to support the fact that drug effects are closely related to metabolic enzymes suggested the possibility for a new approach to the study drug combinations. Therefore, in this paper we suggest a novel approach for analyzing drug combinations using a metabolic network in a systematic manner. The influence of a drug on the metabolic network is described using the distance between the drug target and an enzyme. Target-enzyme distances are converted into influence scores, and from these scores we calculated the correlations between drugs. The result shows that the influence score derived from the targetenzyme distance reflects the mechanism of drug action onto the metabolic network properly. In an analysis of the correlation score distribution, efficacious drug combinations tended to have low correlation scores, and this tendency corresponded to the known properties of the drug combinations. These facts suggest that our approach is useful for prediction drug combinations with an advanced understanding of drug mechanisms.
- Ashburn, T. T., and Thor, K. B. (2004). Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov 3, 673-683. https://doi.org/10.1038/nrd1468
- Li, J. W., and Vederas, J. C. (2009). Drug discovery and natural products: end of an era or an endless frontier? Science 325, 161-165. https://doi.org/10.1126/science.1168243
- Zimmermann, G. R., Lehár, J., and Keith, C. T. (2007). Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today 12, 34-42. https://doi.org/10.1016/j.drudis.2006.11.008
- Lehar, J., Krueger, A. S., Avery, W., Heilbut, A. M., Johansen, L. M., Price, E. R., Rickles, R. J., Short, G. F., 3rd, Staunton, J. E., Jin, X., et al. (2009). Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nat Biotechnol 27, 659-666. https://doi.org/10.1038/nbt.1549
- Zhao, X. M., Iskar, M., Zeller, G., Kuhn, M., van Noort, V., and Bork, P. (2011). Prediction of drug combinations by integrating molecular and pharmacological data. PLoS Comput Biol 7, e1002323. https://doi.org/10.1371/journal.pcbi.1002323
- Zhang, B. B., Zhou, G., and Li, C. (2009). AMPK: an emerging drug target for diabetes and the metabolic syndrome. Cell Metab 9, 407-416. https://doi.org/10.1016/j.cmet.2009.03.012
- Robert, C., Green, M. (2005). Diagnosis and Management of Alzheimer's Disease and Other Dementias. 2 Edition.: Professional Communications.
- Vander Heiden, M. G. (2011). Targeting cancer metabolism: a therapeutic window opens. Nat Rev Drug Discov 10, 671-684. https://doi.org/10.1038/nrd3504
- Chong, Z. Z., Wang, S., Shang, Y. C., and Maiese, K. (2012). Targeting cardiovascular disease with novel SIRT1 pathways. Future Cardiol 8, 89-100. https://doi.org/10.2217/fca.11.76
- Chang, R. L., Xie, L., Bourne, P. E., and Palsson, B. O. (2010). Drug offtarget effects predicted using structural analysis in the context of a metabolic network model. PLoS Comput Biol 6, e1000938. https://doi.org/10.1371/journal.pcbi.1000938
- Folger, O., Jerby, L., Frezza, C., Gottlieb, E., Ruppin, E., and Shlomi, T. (2011). Predicting selective drug targets in cancer through metabolic networks. Mol Syst Biol 7, 501.
- Gottlieb, A., Stein, G. Y., Oron, Y., Ruppin, E., and Sharan, R. (2012). INDI: a computational framework for inferring drug interactions and their associated recommendations. Mol Syst Biol 8, 592.
- Bibi, Z. (2008). Role of cytochrome P450 in drug interactions. Nutr Metab (Lond) 5, 27. https://doi.org/10.1186/1743-7075-5-27
- Barabasi, A. L., and Oltvai, Z. N. (2004). Network biology: understanding the cell's functional organization. Nat Rev Genet 5, 101-113. https://doi.org/10.1038/nrg1272
- Huang, J., Niu, C., Green, C. D., Yang, L., Mei, H., and Han, J. D. (2013). Systematic Prediction of Pharmacodynamic Drug-Drug Interactions through Protein-Protein-Interaction Network. PLoS Comput Biol 9, e1002998. https://doi.org/10.1371/journal.pcbi.1002998
- Liu, Y., Hu, B., Fu, C., and Chen, X. (2010). DCDB: drug combination database. Bioinformatics 26, 587-588. https://doi.org/10.1093/bioinformatics/btp697
- Jia, J., Zhu, F., Ma, X., Cao, Z., Li, Y., and Chen, Y. Z. (2009). Mechanisms of drug combinations: interaction and network perspectives. Nat Rev Drug Discov 8, 111-128. https://doi.org/10.1038/nrd2683
- Mathivanan, S., Ahmed, M., Ahn, N. G., Alexandre, H., Amanchy, R., Andrews, P. C., Bader, J. S., Balgley, B. M., Bantscheff, M., Bennett, K. L., et al. (2008). Human Proteinpedia enables sharing of human protein data. Nat Biotechnol 26, 164-167. https://doi.org/10.1038/nbt0208-164
- Duarte, N. C., Becker, S. A., Jamshidi, N., Thiele, I., Mo, M. L., Vo, T. D., Srivas, R., and Palsson, B. O. (2007). Global reconstruction of the human metabolic network based on genomic and bibliomic data. Proc Natl Acad Sci U S A 104, 1777-1782. https://doi.org/10.1073/pnas.0610772104
- Wolfram Research, I. (2010). Mathematica Edition: Version 8.0. Champaign, Illinois: Wolfram Research, Inc.